|Day Low/High||20.20 / 20.77|
|52 Wk Low/High||11.60 / 24.57|
Investors in Retrophin, Inc. saw new options begin trading this week, for the February 17th expiration.
Investors in Retrophin, Inc. saw new options begin trading today, for the January 2019 expiration.
Phase 3 trial expected to initiate before year-end 2016
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BTX, CARB, GHC, IPHS, PLPC, PXD, RP Downgrades: AIQ, EGL, ESIO, ETSY, MTRX, PKOH, RTRX, USAK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Stocks in the health care sector are vulnerable to declines following the 2016 presidential election, according to S&P analyst Scott Kessler.
Shares of Retrophin surged Wednesday after announcing positive results for its drug that treats a rare kidney disease.
Leerink raised its price target on Retrophin's (RTRX) stock Wednesday after the company's sparsentan drug that treats a rare kidney disease saw positive results in a phase II clinical trial.
Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Trade-Ideas LLC identified Retrophin (RTRX) as a weak on high relative volume candidate
RE-024 treatment associated with clinically meaningful improvements in two PKAN patients